Jasper Therapeutics shares surge 11.05% intraday on positive preliminary data from ETESIAN and BEACON studies.

Jasper Therapeutics (JSPR) surged 11.05% intraday following the release of positive preliminary data from its ETESIAN study of Briquilimab in asthma and findings from the BEACON study, announced 16 days prior. The company also disclosed plans to host an investor webinar on December 2nd to present these results, reinforcing investor optimism about its pipeline progress. These developments, combined with recent insider stock purchases and cost-cutting measures to extend its cash runway, likely drove the sharp intraday rally. While a securities investigation by Bronstein, Gewirtz & Grossman was reported, the immediate price reaction aligns with the clinical and corporate updates rather than the legal inquiry.